August 1, 2024 03:12 PM EDT
Pharma
FDA+

GSK scores ex­pand­ed la­bel for Jem­per­li in first-line en­dome­tri­al can­cer

Katherine

News Reporter

GSK’s Jem­per­li can now be used as a first-line treat­ment for all adult en­dome­tri­al can­cer pa­tients fol­low­ing an ex­pand­ed la­bel ap­proval in the US. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

House pass­es Biose­cure Act, send­ing Chi­nese biotech ban to Sen­ate

As­traZeneca, Gilead de­tail TROP2 ADC da­ta in lung can­cer as they search for new ways for­ward

Mer­ck, Dai­ichi Sankyo de­tail Phase 2 ADC re­sults in small cell lung can­cer, bis­pe­cif­ic com­bo strat­e­gy

Lil­ly again hires from with­in for CFO post, el­e­vat­ing 23-year com­pa­ny vet­er­an

Terns’ oral GLP-1 pass­es Phase 1 test with promis­ing weight loss af­ter one month

GSK says long-act­ing asth­ma hope­ful sig­nif­i­cant­ly cut at­tacks

A service from the Financial Times